• Target：
• Integrin β3

• Fields：
• >>Rap1 signaling pathway;>>Phagosome;>>PI3K-Akt signaling pathway;>>Osteoclast differentiation;>>Focal adhesion;>>ECM-receptor interaction;>>Platelet activation;>>Neutrophil extracellular trap formation;>>Hematopoietic cell lineage;>>Regulation of actin cytoskeleton;>>Thyroid hormone signaling pathway;>>Human cytomegalovirus infection;>>Human papillomavirus infection;>>Herpes simplex virus 1 infection;>>Proteoglycans in cancer;>>MicroRNAs in cancer;>>Hypertrophic cardiomyopathy;>>Arrhythmogenic right ventricular cardiomyopathy;>>Dilated cardiomyopathy;>>Fluid shear stress and atherosclerosis

• Gene Name：
• ITGB3 GP3A

• Protein Name：
• Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)

• Human Gene Id：
• 3690

• Human Swiss Prot No：
• P05106

• Immunogen：
• Synthesized peptide derived from human CD61 AA range: 1-100

• Specificity：
• The antibody can specifically recognize human CD61 protein.

• Source：
• Mouse, Monoclonal/IgG1, kappa

• Purification：
• The antibody was affinity-purified from ascites by affinity-chromatography using specific immunogen.

• Storage Stability：
• 2°C to 8°C/1 year

• Background：
• The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008],

• Function：
• disease:Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. Its inheritance is autosomal recessive. It is characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT variants have normal or near normal (60-100%) expression of dysfunctional receptors.,function:Int

• Subcellular Location：
• Cytoplasmic

• Expression：
• Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs